In contrast, serum tumor biomarker testing offers a noninvasive diagnostic methods known for its simplicity and convenience, playing a pivotal role in the early detection of various malignancies.[8] Currently, the extensively studied biomarkers for BC are CEA and CA15-3.[9] Nevertheless, the role of CEA and CA15-3 remains contentious due to their limited sensitivity and specificity, especially in early-stage BC.[9,10] Consequently, researchers are actively exploring novel biomarkers to improve the early detection of BC. Here, CEACAM5 is linked to breast cancer.